Role of glycosaminoglycans (GAGs) in regulation of the immunogenicity of human vascular endothelial cells

Clinical and Experimental Immunology

Volumn 104, Issue 1, 1996, Pages 60-65

  Rix, D A ^a   Douglas, M S ^a   Talbot, D ^a   Dark, J H ^a   Kirby, J A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

class II MHC antigen; endothelium; glycosaminoglycan; intercellular adhesion molecule 1; interferon gamma; lymphocyte adhesion

Indexed keywords

GAMMA INTERFERON; GLYCOSAMINOGLYCAN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ADHESION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; NEWBORN; NORMAL HUMAN; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0029866876     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-641.x     Document Type: Article

References (28)

1. Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Science 1992; 102:821-32.
2. Gallagher JT, Walker A. Molecular distinctions between heparan sulphate and heparin. Biochem J 1985; 230:665-74.
3. Gallagher JT, Lyon M, Steward WP. Structure and function of heparan sulphate proteoglycans. Biochem J 1986; 236:313-25.
4. Spillman D, Lindahl U. Glycosaminoglycan-protein interactions: a question of specificity. Curr Opin Struct Biol 1994; 4:677-82.
5. Lindahl U, Hook M. Glycosaminoglycans and their binding of biological macromolecules. Ann Rev Biochem 1984; 477:387-417.
6. Lortat-Jacob H, Grimaud JA. Interferon-γ C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-γ protect, relax the cytokine and regulate its activity. Cell Mol Biol 1991; 37:253-60.
7. Lantz M, Thysell H, Nilsson E, Olsson I. On the binding of tumour necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88:2026-31.
8. Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-1a, IL-1b, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992; 22:3027-31.
9. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β Nature 1993; 361:79-82.
10. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993; 11:767-804.
11. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiological flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991; 65:859-73.
12. + allogeneic vascular endothelium. Transplantation 1993; 56:128-34.
13. Savage COS, Brooks CJ, Harcourt GC, Picard JK, King W, Sansom DM, Willcox N. Human vascular endothelial cells process and present autoantigen to human T cell lines. Int Immunol 1995; 7:471-9.
14. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-56.
15. Ikuta S, Kirby JA, Shenton BK, Givan AL, Lennard TWJ. Human endothelial cells: effect of TNF-α on peripheral blood mononuclear cell adhesion. Immunology 1991; 73:71-76.
16. Cui YC, Tai PC, Gatter KC, Mason DY, Spry CJF. A vascular endothelial cell antigen with restricted distribution in human foetal, adult and malignant tissues. Immunology 1983; 49:183-9.
17. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50:537-44.
18. Adams DH, Harvath L, Bottaro DP et al. Hepatocyte growth factor and macrophage inflammatory protein 1-β - structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T-cells. Proc Natl Acad Sci USA 1994; 91:7144-8.
19. Korlipara LVP, Pleass HCC, Taylor RMR, Forsythe JLR, Proud G, Kirby JA. Cultured endothelium: heparin antagonises the induction of Class II molecules by interferon-γ. Transplantation 1994; 58:1426-9.
20. Daubener W, Nockemann S, Gutsche M, Hadding U. Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-γ. Eur J Immunol 1995; 25:688-92.
21. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene 'intercrine' cytokine family. Ann Rev Immunol 1991; 9:617-48.
22. Lortat-Jacob H, Grimaud JA. Interferon-γ binds to heparan sulphate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Letters 1991; 280:152-4.
23. Lortat-Jacob H, Grimaud JA. Binding of interferon-γ to heparan sulfate is restricted to the heparin-like domains and involves carboxylic - but not N-sulfated - groups. Biochim Biophys Acta 1992; 1117:126-30.
24. Ruoslahti E, Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991; 64:867-9.
25. Lortat-Jacob H, Kleinman HK, Grimaud JA. High-affinity binding of interferon-γ to a basement membrane complex (Matrigel). J Clin Invest 1991; 87:878-83.
26. Cohen S, Benacerraf B, McCluskey RT, Ovary Z. Effect of anticoagulants on delayed hypersensitivity reactions. J Immunol 1967; 98:351-8.
27. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, Cohen IR. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83:752-6.
28. Lagodzinski Z, Gorski A, Wasik M. Immunosuppressive action of low-dose heparin: effect on skin allograft survival. Transplantation 1990; 50:714-5.